Engineered immune cells take on tough lupus cases
NCT ID NCT05858684
First seen Jun 09, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new treatment called GC012F (CD19-BCMA CAR-T cells) for people with refractory systemic lupus erythematosus (SLE) — lupus that hasn't improved with standard treatments. The study will enroll 18 participants to find the safest dose and monitor side effects. Researchers will also check if the treatment reduces lupus disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University
RECRUITINGShanghai, Shanghai Municipality, 200001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GC012F injection (CD19-BCMA CAR-T cells)
What this could lead to
If it works, this could offer a new treatment option for people with severe lupus that hasn't responded to other therapies.
What could go wrong
This is a very early, small trial (18 people) focused on safety, not yet proven effective. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.